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 Membranes of higher eukaryotic cells contain glycero-
lipids, sterols, and sphingolipids. For each of these lipid 
 Abstract  The membrane lipid glucosylceramide (GlcCer) 
is continuously formed and degraded. Cells express two 
GlcCer-degrading   -glucosidases, glucocerebrosidase (GBA) 
and GBA2, located in and outside the lysosome, respec-
tively. Here we demonstrate that through transglucosylation 
both GBA and GBA2 are able to catalyze in vitro the transfer 
of glucosyl-moieties from GlcCer to cholesterol, and vice 
versa. Furthermore, the natural occurrence of 1- O -cholesteryl-
  -D-glucopyranoside (GlcChol) in mouse tissues and human 
plasma is demonstrated using LC-MS/MS and  13 C 6 -labeled 
GlcChol as internal standard. In cells, the inhibition of GBA 
increases GlcChol, whereas inhibition of GBA2 decreases 
glucosylated sterol. Similarly, in GBA2-defi cient mice, 
GlcChol is reduced. Depletion of GlcCer by inhibition of 
GlcCer synthase decreases GlcChol in cells and likewise in 
plasma of inhibitor-treated Gaucher disease patients. In tis-
sues of mice with Niemann-Pick type C disease, a condition 
characterized by intralysosomal accumulation of choles-
terol, marked elevations in GlcChol occur as well. When ly-
sosomal accumulation of cholesterol is induced in cultured 
cells, GlcChol is formed via lysosomal GBA. This illustrates 
that reversible transglucosylation reactions are highly de-
pendent on local availability of suitable acceptors.  In con-
clusion, mammalian tissues contain GlcChol formed by 
transglucosylation through   -glucosidases using GlcCer as 
donor. Our fi ndings reveal a novel metabolic function for 
GlcCer. —Marques, A. R. A., M. Mirzaian, H. Akiyama, P. 
Wisse, M. J. Ferraz, P. Gaspar, K. Ghauharali-van der Vlugt, 
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endoplasmic reticulum in hepatocytes ( 22 ), at the endo-
plasmic reticulum and Golgi apparatus in HEK293 cells 
overexpressing enzyme ( 25 ), and at the endosomes in fi -
broblasts and COS-7 cells ( 23 ). GBA2 degrades GlcCer 
without need for an activator protein, and further differs 
from GBA in noted artifi cial substrate and inhibitor speci-
fi city ( 21 ). Finally, some tissues express the enzyme GBA3, 
also referred to as broad-specifi c cytosolic   -glucosidase 
( 26 ). This enzyme shows relatively poor in vitro hydrolytic 
activity toward GlcCer and is thought to be primarily in-
volved in detoxifi cation of glucosylated xenobiotics ( 26 ). 
All three human retaining   -glucosidases employ the double 
displacement mechanism in catalysis. There are many docu-
mented examples of transglucosylation mediated by re-
taining glycosidases ( 27 ). Therefore, theoretically, in addition 
to GBA, GBA2 and GBA3 might also generate GlcChol . 
 Modifi cation of cholesterol by glucosylation changes 
the physicochemical properties of the sterol, rendering 
it far more water soluble. Given the potential physiologi-
cal relevance, the natural occurrence of GlcChol and its 
metabolism in cells and tissues are of interest. We there-
fore studied the existence of the glucosylated sterol in 
mammalian tissues. For this purpose  13 C 6 -isotope-labeled 
GlcChol was synthesized to be used as internal standard in 
sensitive quantitative detection of GlcChol by LC-MS/MS. 
Here we demonstrate the natural occurrence of GlcChol 
in mammalian cells and tissues. Moreover, we document 
the ability of both GBA and GBA2 to degrade, as well as 
synthesize, GlcChol. The importance of substrate and ac-
ceptor concentrations regarding the action of GBA and 
GBA2 in GlcChol metabolism is experimentally demon-
strated. Our investigation demonstrates the surprising ver-
satility of   -glucosidases, a fi nding discussed in relation to 
metabolism of sphingolipids and sterols in health and 
disease. 
 MATERIALS AND METHODS 
 Materials 
 The 25-NBD-cholesterol,  N -[6-[(7-nitro-2-1,3-benzoxadiazol-
4-yl)amino]hexanoyl]D-glucosyl-  1-1 ′ -sphingosine (C6-NBD-
GlcCer),  N -[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]
D-erythro-sphingosine (C6-NBD-Cer), D-glucosyl-  -1,1 ′  N -palmi-
toyl-D- erythro -sphingosine (C16:0-GlcCer), and D-glucosyl-  -1,1 ′ N -
oleoyl-D- erythro -sphingosine (C18:1-GlcCer) were purchased from 
Avanti Polar Lipids (Alabaster, AL). The 4-methylumbelliferyl   -
D-glucopyranoside (4MU-Glc) was purchased from Glycosynth™ 
(Winwick Quay Warrington, Cheshire, UK). Conduritol B epox-
ide (CBE; D,L-1,2-anhydro- myo -inositol;) was from Enzo Life Sci-
ences Inc. (Farmingdale, NY), GlcChol (  -cholesteryl glucoside, 
  -GlcChol) and ammonium formate (LC-MS quality) were from 
Sigma-Aldrich (St. Louis, MO).  N -( n -butyl)deoxygalactonojirimy-
cin (NB-DGJ) was purchased from Toronto Research Chemicals 
(Toronto, Canada). GBA2 inhibitor,  N -(5-adamantane-1-yl-
methoxy-pentyl)-deoxynojirimycin (AMP-DNM), and GBA3 inhi-
bitor,   -1-C-nonyl-DIX (anDIX), were chemically synthesized in 
the department of Bio-organic Synthesis at the Faculty of Sci-
ence, Leiden Institute of Chemistry at the University of Leiden 
(Leiden, The Netherlands). Cerezyme ® , a recombinant human 
classes, monoglucosylated structures have been reported. 
Glucosylceramide (GlcCer), the intermediate in biosyn-
thesis and degradation of more complex glycosphingolip-
ids (GSLs), is ubiquitous in mammalian cells, particularly 
located in the cell membrane ( 1 ). Its presence in plants 
and some fungi is also documented. Glucosyldiacylglyc-
erol has been identifi ed in various plants, but its presence 
in mammalian cells is comparatively poorly documented 
( 2, 3 ). Likewise, sterol-glucosides are known to occur in 
plants and fungal species ( 4 ), but their existence in mam-
malian cells has not been extensively studied. Indications 
of the existence of glucosyl-  -D-cholesterol or 1- O -cholesteryl-
  -D-glucopyranoside (GlcChol) in mammalian cells were 
fi rst provided by Murofushi and coworkers ( 5, 6 ). They 
described its occurrence in cultured human fi broblasts 
and gastric mucosa ( 5, 6 ). Heat shock was found to in-
crease biosynthesis of GlcChol and, subsequently, induce 
HSP70 ( 7 ). GlcCer is formed by the enzyme GlcCer syn-
thase (GCS, EC2.4.1.80). This transferase, fi rst cloned by 
Hirabayashi and colleagues ( 8 ), is located at the cytosolic 
leafl et of the Golgi apparatus where it transfers the glucose-
moiety from UDP-glucose to ceramide ( 9 ). In a recent 
study, Akiyama et al. ( 10 ) showed that GCS does not syn-
thesize GlcChol. They noticed that GM-95 cells defi cient in 
GCS are unable to synthesize GlcChol without the addition 
of exogenous GlcCer. Furthermore, the same researchers 
demonstrated that, at least in vitro, the lysosomal enzyme 
glucocerebrosidase (GBA; E.C.3.2.1.45) generates, through 
transglucosylation, 25-[ N -[(7-nitro-2-1,3-benzoxadiazol-4-yl) 
methyl] amino]-27-norcholesterol (25-NBD-cholesterol)-
glucoside from GlcCer and artifi cial 25-NBD-cholesterol 
( 11 ). Such ability of GBA to perform transglucosylation 
was earlier demonstrated by Glew and coworkers, show-
ing catalyzed transfer of the glucose moiety from 4-
methylumbelliferyl-  -glucoside to retinol and other alco-
hols ( 12 ). 
 The enzyme GBA is well-studied because its defi ciency 
underlies Gaucher disease (GD), a relatively common lyso-
somal storage disease ( 13 ). Assisted by the small activator 
protein, saposin C, GBA degrades GlcCer to ceramide and 
glucose in lysosomes, the penultimate step in GSL catabo-
lism ( 13 ). Defi cient GBA activity in GD patients conse-
quently results in accumulation of GlcCer in lysosomes, 
most prominently in macrophages. These “Gaucher cells” 
secrete specifi c proteins, as well as glucosylsphingosine 
(GlcSph), the deacylated form of GlcCer ( 14–16 ). The 
non-neuronopathic (type 1) variant of GD is presently 
treated by enzyme replacement therapy (ERT), implying 
chronic twice-weekly intravenous infusion of macrophage-
targeted recombinant enzyme ( 17 ). An alternative treat-
ment of type 1 GD, named substrate reduction, is based on 
oral administration of an inhibitor of GCS ( 18–20 ). 
 Mammalian cells and tissues contain other   -glucosidases 
besides GBA that degrade GlcCer. All cells express the 
membrane-associated nonlysosomal glucosylceramidase, 
named GBA2 ( 21–23 ). This enzyme is not defi cient in GD 
patients. In fact, a compensatory overexpression of GBA2 
in materials of GD has been reported ( 24 ). GBA2 has been 
found to be located outside lysosomes, being noted at the 
 at W
alaeus Library / BIN 299, on Septem
ber 20, 2016
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2016/01/02/jlr.M064923.DC1
Supplemental Material can be found at:
Glucosylated cholesterol metabolism by   -glucosidases 453
room with a 12 h light/dark cycle and given access to food and 
water ad libitum. All animal protocols were approved by the Insti-
tutional Animal Welfare Committee of the Academic Medical 
Centre Amsterdam in the Netherlands (DBC101698, DBC100757-
115, DBC100757-125, and DBC17AC) 
 The generation of the GD1 mouse model has been described 
previously ( 32, 33 ). Mice were maintained in individually venti-
lated cages with ad libitum food and water in the animal facility 
at Lund University Biomedical Center. Breeding and experimen-
tal procedures were approved by the Committee for Animal Eth-
ics in Malmö/Lund, Sweden. 
 Animals were fi rst anesthetized with a dose of Hypnorm (0.315 
mg/ml phenyl citrate and 10 mg/ml fl uanisone) and Dormicum 
(5 mg/ml midazolam) according to their weight. The given dose 
was 80   l/10 g bodyweight. Animals were euthanized by cervical 
dislocation. Organs were collected by surgery, rinsed with PBS, 
directly snap-frozen in liquid nitrogen, and stored at   80°C. 
Later, homogenates were made from the frozen material in 
25 mM potassium phosphate buffer (pH 6.5), supplemented 
with 0.1% (v/v) Triton X-100 and protease inhibitors (4   l of 
buffer per 1 mg of tissue). 
 Cloning of cDNAs encoding GBA2, GBA3, and UGCG 
 The design of cloning primers was based on NCBI reference 
sequences NM_172692.3 for murine GBA2, NM_020973.3 for hu-
man hGBA3, and NM_003358.2 for human UGCG (GCS). Using 
the primers listed below, the full-length coding sequences were 
cloned into pcDNA3.1/Myc-His (Invitrogen, Life Technologies, 
Carlsbad, CA), using primers:  RB143 , GAATTCGCCGCCACC-
ATGGTAACCTGCGTCCCGG and  RB144 , GCGGCCGCTCTG-
AATTGAGGTTTGCCAG for mGBA2;  RB252 , GAATTCGCCGC-
CACCATGGCTTTCCCTGCAGGATTTG and  RB253 , GCGGCC-
GCTACAGATGTGCTTCAAGGCC for hGBA3;  RB111 , TCCT-
GCGGGAGCGTTGTC and  RB114 , GGTACCTACATCTAGGA-
TTTCCTCTGC for hUCGC. These constructs were used to 
transfect COS-7 cells. 
 For the transfection of Chinese hamster ovary cells (CHO-K1 
cells), the full-length coding sequence for transcript variant 1 of 
human GBA3 (NM_020973.3) was cloned into p3xFLAG-CMV-14 
(Sigma-Aldrich) as described previously ( 11 ). 
 Cell culture and transfection 
 RAW264.7 cells were obtained from the American Type Culture 
Collection and were cultured in DMEM (Life Technologies, 
Carlsbad, CA) supplemented with 10% FBS (Bodinco, Alkmaar, 
The Netherlands) with penicillin/streptomycin (Life Technologies). 
COS-7 cells were cultured in Iscove’s modifi ed Dulbecco’s medium 
GBA (rGBA), was obtained from Genzyme (Genzyme Nederland, 
Naarden, The Netherlands). Cholesterol traffi cking inhibitor, 
U18666A, and methyl-  -cyclodextrin were from Sigma-Aldrich 
Chemie GmbH. LC-MS-grade methanol, 2-propanol, water, and 
HPLC-grade chloroform were purchased from Biosolve, and am-
monium formate (LC-MS grade) from Sigma-Aldrich Chemie 
GmbH. 
 Synthesis of  13 C 6 isotope-labeled   -cholesteryl glucoside 
 The synthesis of  13 C-labeled glucosyl donor  4 (see  Scheme 1 ) 
commences with protecting the fi ve hydroxyls in glucose  1 as 
the benzoyl esters using pyridine and benzoyl chloride to give 
1,2,3,4,6-penta- O -benzoyl-  -D- 13 C 6 -glucopyranoside  2 quantitatively. 
In the next step the anomeric benzoate was selectively removed 
using hydrazine acetate providing 2,3,4,6-tetra- O -benzoyl-  /  -D-
 13 C 6 -glucopyranoside  3 in 82% yield. The anomeric hydroxyl in  3 
was transformed into the corresponding trichloroacetimidate us-
ing trichloroacetonitrile and 1,8-diazabicyclo[5.4.0]undec-7-ene as 
base, giving 2,3,4,6-tetra- O -benzoyl-1-(2,2,2-trichloroethanimidate)-
  -D- 13 C 6 -glucopyranoside  4 . In the penultimate step, cholesterol 
was reacted with  4 under the agency of a catalytic amount of trimeth-
ylsilylmethanesulphonate in dichloromethane at room tempera-
ture. After 1 h, the reaction was quenched with triethylamine and 
the mixture purifi ed by silica gel column chromatography giving 
cholesteryl 2,3,4,6-tetra- O -benzoyl-  -D- 13 C 6 -glucopyranoside  5 in 
83%. Compound  5 was deprotected using sodium methoxide in 
methanol/dichloromethane giving, after silica gel column chroma-
tography, the title compound, cholesteryl-  -D- 13 C 6 -glucopyranoside 
( 13 C 6 -GlcChol)  6 as a white solid in 94%. 
 Animal studies 
 Npc1   /   mice ( Npc1 nih and  Npc1 spm ), along with WT littermates 
( Npc1 +/+ ), were generated by crossing  Npc1 +/   males and females 
in-house . The heterozygous BALB/c Nctr- Npc1 m1N /J mice (stock 
number 003092) and heterozygous C57BLKS/J- Npc1 spm /J (stock 
number 002760) were obtained from the Jackson Laboratory 
(Bar Harbor, ME). Mouse pups were genotyped according 
to published protocols ( 29, 30 ). The  Gba2   /   mice (C57Bl/6-
129S6/SvEv mixed background) were generated as previously 
described ( 22 ). Breeding pairs of LIMP-2 were kindly provided 
by Prof. Paul Saftig (Kiel, Germany) ( 31 ). Homozygous WT ani-
mals (LIMP2 +/+ ) and homozygous animals (LIMP2   /   ) were gen-
erated by crossing heterozygous (LIMP2 +/   ) mice. Genotyping 
was determined by PCR using genomic DNA ( 31 ). Mice (±3 
weeks old) received the rodent AM-II diet (Arie Blok Diervoeders, 
Woerden, The Netherlands). The mice were housed at the Institute 
Animal Core Facility in a temperature- and humidity-controlled 
 Scheme  1. Synthesis of  13 C 6 -GlcChol  6 ( 28 ). 
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according to the method we established previously ( 11 ) with 
slight modifications. The reaction mixture, in a total volume 
of 20   l, contained 100 pmol C6-NBD-GlcCer, 50 mM citrate-
phosphate buffer (pH 6.2), and a desired amount of enzyme. 
After incubation at 37°C for 30 min, the reaction was terminated 
by adding chloroform/methanol (2:1, v/v), and the lipids were 
extracted and analyzed as reported before ( 11 ). 
 Analysis of GlcChol by LC-MS/MS 
 A Waters Acquity TM TQD instrument was used in all experi-
ments. The instrument consisted of a UPLC system combined 
with a tandem quadrupole mass spectrometer as mass analyzer. 
Data were analyzed with Masslynx 4.1 software (Waters Corpora-
tion, Milford, MA). GlcChol and  13 C 6 -GlcChol (internal stan-
dard) were separated using a BEH C18 reversed-phase column 
(2.1 × 50 mm, particle size 1.7   m; Waters Corporation), by ap-
plying an isocratic elution of mobile phases, 2-propanol:water 
90:10 (v/v) containing 10 mM ammonium formate (eluent A) 
and methanol containing 10 mM ammonium formate (eluent 
B). The UPLC program was applied during 5 min consisting of 
10% A and 90% B. The divert valve of the mass spectrometer was 
programmed to discard the UPLC effl uent before (0–0.25 min) 
and after (4–5 min) the elution of the analytes to prevent system 
contamination. The fl ow rate was 0.250 ml/min and the reten-
tion time of both GlcChol and the internal standard was 1.43 min 
( Fig. 1C ). The column temperature and the temperature of the 
autosampler were kept at 23°C and 10°C, respectively, during the 
run. 
 Solutions of GlcChol and  13 C 6 -GlcChol and a mixture of both 
compounds were prepared with concentrations of 1 pmol/  l in 
5 mM ammonium formate in methanol. The compounds were 
introduced in the mass spectrometer by direct infusion and the 
optimal tuning conditions for both compounds in ES + (electro-
spray positive) mode were determined ( Table 1 ). The most abun-
dant species for both compounds were ammonium adducts, 
[M+NH 4 ] 
+ ,  m/z 566.6 > 369.4 for GlcChol and  m/z 572.6 > 369.4 
for  13 C 6 -GlcChol (see also  Fig. 1B ). The product ion represents 
the cholesterol part of the molecule after loss of the glucose 
moiety. Because the  13 C isotopes are on the glucose molecule, 
the daughter fragment of  13 C 6 -GlcChol has the same  m/z ratio of 
369.4. 
 Confi rmation of compounds with  m/z 566.6 > 369.4 being 
GlcChol was performed by demonstration of complete digestion 
to cholesterol using excess rGBA at pH 5.2 (McIlvaine buffer). 
The release of glucose was confi rmed by a glucose oxidase assay. 
with 5% FBS and penicillin/streptomycin under 5% CO 2 at 37°C. 
Cells were seeded at 75% confl uence in 6-well plates and trans-
fected using FuGENE ® 6 transfection reagent (Promega Bene-
lux, Leiden, The Netherlands) according to the manufacturer’s 
instructions, at a FuGENE:DNA ratio of 3:1. After 24 h, inhibitors 
of GBA (CBE, 300   M) or GBA2 (AMP-DNM, 20 nM) were added 
and 48 h later, the medium was removed, cells were washed three 
times with ice-cold PBS and harvested by scraping in 25 mM po-
tassium-phosphate buffer (pH 6.5). CHO-K1 cells (RCB0285, es-
tablished by T. T. Puck) were purchased from RIKEN BioRe-
source Center (Ibaraki, Japan) and cultured in Ham’s F-12 me-
dium (Nissui) supplemented with 10% FBS under 5% CO 2 at 
37°C. cDNA transfection for CHO-K1 cells was carried out using 
Lipofectamine ® 2000 transfection reagent (Life Technologies) 
according to the manufacturer’s instructions. After 24 h, me-
dium containing transfection reagents was removed and cells 
were incubated with lysis buffer [50 mM Tris-HCl, 150 mM NaCl, 
1 mM EDTA, 1% Triton X-100, 1 tablet/10 ml Complete Prote-
ase Inhibitor Cocktail Tablets (Roche, Basel, Switzerland) (pH 
7.4)] for 15–30 min at 4°C after washing with PBS. The cells were 
harvested and centrifuged at 12,000  g for 10 min at 4°C. The ob-
tained supernatants were collected for in vitro enzyme assays. 
 In vitro assay of transglucosylase activity 
 Lysates of COS-7 cells overexpressing GBA2, GBA3, GCS, and 
rGBA were used to determine transglucosylase activity of each 
enzyme. The assay was performed as described earlier ( 11 ) with a 
few modifi cations. First, 40   l of homogenate of cells overex-
pressing GBA2, GBA3, or GCS was preincubated with 10   l of 
25 mM CBE in water for 20 min (samples containing diluted 
rGBA were preincubated in the absence of CBE). To each of the 
samples, 200   l of the appropriate buffer containing 100   M of 
donor (either C18:1-GlcCer or GlcChol) and 40   M of acceptor 
(either 25-NBD-cholesterol or C6-NBD-Cer) were added. Trans-
glucosylase activity of GBA2-overexpressing cells was measured in 
a 150 mM McIlvaine buffer (pH 5.8) and the assay for rGBA was 
done in a 150 mM McIlvaine buffer (pH 5.2) containing 0.1% 
BSA, 0.1% Triton X-100, and 0.2% sodium taurocholate. For 
GBA3, the assay contained 100 mM HEPES buffer (pH 7.0). The 
transglucosylase assay for GCS was performed in a 125 mM potas-
sium-phosphate buffer (pH 7.5) with 12.5 mM UDP-glucose, 6.25 
mM MgCl 2 , 0.125% BSA, and 0.625% CHAPS. After 1 h of incu-
bation at 37°C, the reaction was terminated by addition of chlo-
roform/methanol (1:1, v/v) and lipids were extracted according 
to Bligh and Dyer ( 34 ). Thereafter, lipids were separated by TLC 
on HPTLC silica gel 60 plates (Merck, Darmstadt, Germany) us-
ing chloroform/methanol (85:15, v/v) as eluent followed by de-
tection of NBD-labeled lipids using a Typhoon variable mode 
imager (GE Healthcare Bio-Science Corp., Piscataway, NJ) ( 35 ). 
 Identifi cation of newly formed fl uorescent lipid in transgluco-
sylation assays with 25-NBD-cholesterol as acceptor was per-
formed following its isolation by scraping from plates by demon-
stration of complete digestion to NBD-cholesterol using excess 
rGBA at pH 5.2 (McIlvaine buffer) in the presence of 0.2% (w/v) 
sodium taurocholate and 0.1% (v/v) Triton X-100. 
 Lysates of CHO-K1 cells were used to access the transglucosyl-
ase activity and the   -glucosidase activity of GBA3. The assay for 
transglucosylase activity was performed according to the method 
we established previously ( 11 ) with slight modifi cations. The re-
action mixture, in a total volume of 20   l, contained 40   M 
25-NBD-cholesterol, 80   M C16:0-GlcCer, 50 mM citrate-phos-
phate buffer (pH 6.2), 0.5% CHAPS, 2% ethanol, and the de-
sired amount of enzyme. After incubation at 37°C for 20 h, the 
reaction was terminated by adding chloroform/methanol (2:1, 
v/v), and the lipids were extracted and analyzed as reported 
before ( 11 ). The assay for   -glucosidase activity was performed 
 TABLE 1. MS/MS instrument parameters 
Capillary voltage 3.50 KV
Cone voltage 20 V
Source temperature 120°C
Desolvation temperature 450°C
Cone gas 50 l/h
Desolvation gas 950 l/h
Collision gas 0.20 ml/min
Collision voltage 20 V
Type Multiple reaction monitoring
Ion mode ES + (electrospray positive)
Dwell time 0.250 s
Interchannel delay 0.005 s
Interscan delay 0.005 s
Transitions 
 GlcChol, RT (min) 1.43
  13 C 6 -GlcChol, RT (min) 1.43
 Fit weight, RT (min) None
 Smooth method, RT (min) Mean
 Smooth width, RT (min) 2
RT, retention time .
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 Analysis of GlcChol in animal tissues by LC-MS/MS 
 13 C 6 -labeled GlcChol (3 pmol) in methanol was added to 30   l 
of mouse tissue homogenate. Next, lipids were extracted accord-
ing to the method of Bligh and Dyer ( 34 ) and GlcChol was ana-
lyzed by LC-MS, as described above. 
 Analysis of GlcChol in COS-7 cells by LC-MS/MS 
 COS-7 cells overexpressing GBA2 or GCS were homogenized 
by sonication on ice. Prior to extraction, 2 pmol of  13 C 6 -labeled 
GlcChol in methanol (used as an internal standard) was added to 
180   l of homogenate. Next, lipids were extracted according to 
the method of Bligh and Dyer ( 34 ) by addition of methanol, 
chloroform, and water (1:1:0.9, v/v/v) and the lower phase was 
taken to dryness under a stream of nitrogen. Isolated lipids were 
purifi ed by water/butanol extraction (1:1, v/v) and GlcChol was 
analyzed by LC-MS, as described above. 
 Analysis of GlcCer and ceramide in COS-7 cells by HPLC 
 COS-7 cells, overexpressing GBA2 or GCS, were homogenized 
by sonication on ice. Prior to extraction, 1 nmol of C17-sphinga-
nine in methanol (used as an internal standard) was added to 
100   l of homogenate. Next, lipids were extracted according to 
the method of Bligh and Dyer ( 34 ) by addition of methanol, 
chloroform, and water (1:1:0.9, v/v/v) and the lower phase taken 
to dryness under a stream of nitrogen. Isolated lipids were deacyl-
ated in a microwave oven, derivatized, and analyzed by HPLC, as 
described before ( 36 ). 
 Analysis of GlcChol in RAW264.7 cells by LC-MS/MS 
 13 C 6 -labeled GlcChol (3 pmol) in methanol was added to 100   l 
of RAW264.7 cell lysate. Next, lipids were extracted according to 
the method of Bligh and Dyer ( 34 ) and GlcChol was analyzed by 
LC-MS, as described above. 
 Protein concentration 
 Protein concentration was determined using the Pierce BCA 
protein assay kit (Thermo Scientifi c) by the microplate proce-
dure. Absorbance was measured in an EL808 Ultra microplate 
reader (BIO-TEK Instruments Inc.) at 550 nm . 
 Statistical analysis 
 Values in the fi gures are presented as a mean ± SD. Data were 
analyzed by unpaired Student’s  t -test or Mann-Whitney U test. 
 P values <0.05 were considered signifi cant (* P < 0.05, ** P < 0.01, 
and *** P < 0.001). 
 RESULTS 
 Quantifi cation of GlcChol by LC-MS/MS 
 To establish whether glucosyl-  -D-cholesterol (GlcChol) 
physiologically occurs in mammals, we fi rst developed a 
LC-MS/MS procedure for its quantitative detection. For 
this purpose, a  13 C 6 isotope-labeled GlcChol was synthe-
sized ( 13 C 6 -GlcChol). The use of the isotope-labeled com-
pound as internal standard avoids the need for corrections 
for extraction effi ciency, chromatographic behavior, and 
ionization effi ciency during quantifi cation of GlcChol. To 
prevent undesired adduct formation, lipids were extracted 
in the absence of additional salts. To stimulate formation 
of desired ammonium adduct, we incorporated 10 mM 
ammonium in the eluent. 
 Collection of Niemann-Pick type C and GD patient 
plasma 
 EDTA plasma (15 males and 3 females) was collected prior to 
therapy from Dutch patients suffering from type 1 GD, known by 
referral to the Academic Medical Center. Diagnosis of GD in pa-
tients was confi rmed by genotyping and demonstration of defi -
cient GBA activity in leukocytes or fi broblasts. Plasma samples 
were stored frozen at   20°C until further use. EDTA plasma 
samples of 42 male and 47 female control subjects were collected 
at the Academic Medical Center. The EDTA plasma samples of 
15 Niemann-Pick type C (NPC) patients and 9 NPC carriers were 
collected at the Unidad de Investigación Traslacional in Zara-
goza, Spain. 
 The status of affected or carrier of NPC disease was deter-
mined after the exomic sequencing of  NPC1 and  NPC2 genes, 
according to the presence of two mutations or one mutation, re-
spectively. Filipin stainings of fi broblasts were conducted to com-
plete the diagnosis study. Plasma samples were stored frozen at 
  20°C until further use. Approval had been obtained from the 
institutional ethics committee and informed consent according 
to the Declaration of Helsinki. 
 Quantifi cation of total GlcChol in human plasma 
 For quantitative analysis of GlcChol in samples of plasma, we 
developed a LC-MS/MS method using the multiple reaction mon-
itoring (MRM) mode of the transitions mentioned above . First, 
GlcChol was extracted from plasma from a healthy individual ac-
cording the method of Bligh and Dyer ( 34 ) with a few modifi ca-
tions. Plasma (20   l) was pipetted in an Eppendorf tube (2 ml) 
and 20   l of an internal standard solution, containing 0.1 pmol/  l 
of  13 C 6 -GlcChol in methanol, was added, followed by addition of 
280   l methanol and 150   l of chloroform. After brief mixing, 
the sample was left at room temperature for 30 min, mixed oc-
casionally, and centrifuged for 10 min at 15,700  g to spin down 
precipitated protein. The supernatant was transferred to an Ep-
pendorf tube and 150   l chloroform and 250   l water were 
added to induce separation of phases. After centrifugation (5 min 
at 15,700  g ), the lower hydrophobic phase was transferred to a 
clean Eppendorf tube and the upper phase was washed by addi-
tion of 300   l of chloroform. Lower phases were pooled and 
taken to dryness at 35°C under a nitrogen stream. Next, the resi-
due was dissolved in 700   l of butanol and 700   l of water, mixed 
well, and centrifuged for 10 min at 15,700  g . The upper phase 
(butanol) was transferred to a 1 ml tube with screw cap and the 
sample was dried under a gentle stream of nitrogen at 35°C. Sub-
sequently, the residue was dissolved in 150   l of eluent B by mixing 
and sonication, and after centrifugation (5 min at 15,700  g ), an 
aliquot of 100   l was transferred into an UPLC vial with insert. 
Ten microliters of the solution were injected for analysis. 
 Second, for the quantifi cation of GlcChol in plasma, the sam-
ple was spiked with GlcChol (concentrations: 0–2.5–5–10–50–
100–200–1,000 pmol GlcChol/ml of plasma), internal standard 
was added and samples were extracted. The ratio, the area from 
transition GlcChol over the area from the transition  13 C 6 -GlcChol, 
was plotted against the concentration of GlcChol spiked in the 
plasma samples. A linear response was obtained over the entire 
concentration range (y = 0.0108x + 1.9188, R 2 = 0.998). The 
within-run variation (164.2 ± 4.3 pmol/ml with coeffi cient of 
variation % 2.6) and between run variation (166.8 ± 3.6 pmol/ml 
with coeffi cient of variation % 2.2), was determined in plasma of 
a healthy volunteer by 10 repetitive measurements . 
 The limit of detection was 0.5 pmol/ml plasma with a signal-
to-noise ratio of three and the limit of quantitation was 0.9 pmol/
ml plasma with a signal-to-noise ratio of 10. Calculation of the 
signal-to-noise ratio was done using the peak-to-peak method. 
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( 22 ) and LIMP-2 KO mice with markedly reduced GBA 
due to impaired transport to lysosomes ( 31 ). As shown in 
 Fig. 2B–D , the GlcChol concentration was markedly lower 
in all the tissues of GBA2-defi cient animals analyzed com-
pared with WT controls, especially in thymus. In contrast, in 
the GBA-defi cient LIMP-2 KO mice, no reduction in GlcChol, 
but rather a signifi cant increase in liver and plasma levels 
was observed ( Fig. 2C, D ;  P < 0.001 and  P < 0.05, respec-
tively). Mice with an induced GBA defi ciency in the white 
blood cell lineage showed, upon treatment with GCS in-
hibitor Genz-112638 (eliglustat tartrate, Genzyme), partial 
reduction in plasma GlcCer ( 37 ) and an almost statistically 
signifi cant reduction of elevated plasma GlcChol ( Fig. 2E , 
 P = 0.07). An increase in GlcChol was also observed in liver 
( Fig. 2F ,  P < 0.001), spleen, and bone marrow (see supple-
mentary Fig. 1) of mice with induced GD. Correction of 
GBA defi ciency by lentiviral gene therapy under the con-
trol of different promoters led, in all cases, to a concomi-
tant reduction of GlcChol in these tissues ( Fig. 2F ). 
 In vitro transglycosylation by   -glucosidases 
 The enzymes GBA and GBA2 were both found able to 
hydrolyze GlcChol at conditions optimal for degradation 
of 4MU-Glc (supplementary Table 1). 
 Sensitive quantitative measurement of GlcChol proved 
feasible with  13 C 6 isotope-labeled GlcChol as internal stan-
dard, as shown in  Fig. 1A–C . The limit of detection was 0.5 
pmol/ml plasma, with a signal-to-noise ratio of three and 
a limit of quantitation of 0.9 pmol/ml plasma with a sig-
nal-to-noise ratio of 10. GlcChol was found to be an excel-
lent substrate for rGBA (Cerezyme ® ), even at sub-optimal 
conditions (absence of Triton X-100 and sodium tauro-
cholate) ( Fig. 1D ). 
 Demonstration of natural occurrence of GlcChol in mice 
 Next, we examined various tissues of WT mice on the 
presence of GlcChol. Relative high amounts of glucosyl-
ated sterol were noted for thymus, sciatic nerve, brain, and 
lungs (see  Fig. 2A ). The identity of the quantifi ed struc-
ture ( m/z 566.6) in thymus (and other tissues) was con-
fi rmed by its digestion by rGBA, showing that in WT 
animals more than 90% of the lipid measured is indeed 
glucosyl-  -D-cholesterol. However, in sciatic nerve and brain, 
a signifi cant proportion of  m/z 566.6 was not digested by 
rGBA, suggesting that it may represent another glycosyl-
ated cholesterol, for example galactosyl-  -D-cholesterol. 
 The concentration of GlcChol in liver and thymus was 
determined for tissues of WT mice, animals lacking GBA2 
 Fig. 1. Quantifi cation of GlcChol by LC-MS/MS . A: MS scan of pure GlcChol and its  13 C-labeled isotope. 
The ammonium-adduct is the most abundant  m/z for both compounds. The product ion,  m/z 369.4, is the 
common fragment for both compounds. Shown are the parent scans of product ion  m/z 369.4 of GlcChol 
and  13 C 6 -labeled GlcChol, [M+NH 
4 ] + ,  m/z 566.6 for GlcChol, and  m/z 572.6 for  13 C 6 -GlcChol. The [M+H] 
+ 
and [M+Na] + are the minor  m/z . The  m/z 571.6 represents the sodium adduct of GlcChol (a). B: The struc-
ture of GlcChol and its isotope,  13 C 6 -labeled GlcChol, their fragmentation pattern,  m/z 369.4, is the product 
ion of both compounds after loss of glucose moiety. C: Elution pattern of GlcChol ( m/z 566.6 > 369.4) and 
 13 C 6 -labeled GlcChol ( m/z 572.6 > 369.4) from UPLC. D: Linearity of GlcChol quantifi cation and its com-
plete digestion with rGBA (1.0 U/ml) for 18 h at 37°C. 
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generated an additional fluorescent lipid coinciding 
with 25-NBD-cholesterol-glucoside. Inhibition of GBA 
with CBE or GBA2 with AMP-DNM prevented formation 
of 25-NBD-cholesterol-glucoside ( Fig. 3A ). Transglucosylation 
was hardly observed for cell lysates with overexpressed 
GBA3 and GCS ( Fig. 3A ), recapitulating the fi ndings by 
Akiyama and coworkers concerning GCS ( 10 ). We repeated 
the experiment using natural cholesterol as acceptor and 
determined the levels of formed GlcChol by LC-MS ( Fig. 
3B ). Again, GlcChol formation occurred in the presence 
of GBA (inhibitable by CBE) and in cell lysates with high 
GBA2 (inhibitable by AMP-DNM) ( Fig. 3B ). Lysates of 
cells overexpressing GBA3 and GCS showed no additional 
GlcChol formation (supplementary Fig. 2). The pH opti-
mum of GBA and GBA2 to generate GlcChol was next de-
termined (see supplementary Fig. 3). In the case of GBA, 
optimal activity was seen between pH 4.5 and 5.5 and for 
GBA2 between pH 6.0 and 7.0. We investigated, with the 
same assay, whether GlcSph, GalCer, and GalSph also act 
 The fi ndings on GlcChol levels in WT, GBA-defi cient, 
and GBA2-defi cient mice prompted us to study the ability 
of the three   -glucosidases, GBA, GBA2, and GBA3, to 
generate glucosylated cholesterol by transglucosylation. We 
fi rst studied this ability in vitro and reproduced the assay 
of Akiyama and coworkers ( 11 ) using 25-NBD-cholesterol 
as acceptor and detection of 25-NBD-glucosyl-cholesterol 
formation by TLC and fl uorescence scanning . As the 
source of enzyme, we used rGBA and individually overex-
pressed GBA2, GBA3, and GCS in COS-7 cells. Overex-
pression of enzymes was checked by measuring enzymatic 
activity with appropriate assays (not shown). 
 Recombinant enzyme and COS-7 cell lysates were incu-
bated with natural GlcCer (C18:1-GlcCer) as donor and 
25-NBD-cholesterol as acceptor. Following incubation at 
optimal conditions for each enzyme with inclusion of 
UDP-Glc for GCS (see Materials and Methods section), lip-
ids were extracted and subjected to HPTLC. As shown in 
 Fig. 3A , rGBA and cell lysates with overexpressed GBA2 
 Fig. 2. GlcChol in tissues of WT, GBA-defi cient, and GBA2-defi cient mice. A: GlcChol (picomoles per milligram protein) in various tis-
sues of WT male mice at 2 months of age (n = 3, mean ± SD). *A signifi cant proportion of  m/z 566.6 was not digestible by rGBA . B: GlcChol 
(nanomoles per gram wet weight) in thymus of WT,  Gba2   /   , and  Limp2   /   male mice at 2 months of age (n = 3, mean ± SD). C: GlcChol 
(nanomoles per gram wet weight) in liver of WT,  Gba2   /   , and  Limp2   /   male mice at 2 months of age (n = 3, mean ± SD). D: GlcChol (nano-
molar) in plasma of WT,  Gba2   /   , and  Limp2   /   male mice at 2 months of age (n = 3, mean ± SD). E: Plasma GlcChol (nanomolar) in WT 
(n = 27), untreated type 1 GD mice (n = 40), and treated with Genz-112638 (n = 27) (mean ± SD). F: Liver GlcChol (nanomoles per gram 
wet weight) in WT mice (n = 6, mean ± SD), type 1 GD-induced mice untreated (n = 6), type 1 GD mice treated with lentiviral GBA cDNA 
gene therapy with macrophage-specifi c promotor (CD68) (n = 8), ubiquitously expressed human phosphoglycerate kinase (PGK) promo-
tor (n = 12), or   retroviral vector with the viral promoter spleen focus forming virus (SFFV) promotor (n = 8). Data were analyzed using an 
unpaired  t -test. * P < 0.05, ** P < 0.01, and *** P < 0.001. 
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equilibrium reaction in which the glucose moiety is revers-
ibly exchanged between cholesterol and ceramide. 
 We investigated in more detail potential transglucosyl-
ase activity of human GBA3 overexpressed in CHO-K1 
cells. Overexpression of GBA3 increased   -glucosidase ac-
tivity ( Fig. 3D ). As shown in  Fig. 3E , overexpression of 
GBA3 did not affect transglucosylase activity from natural 
GlcCer (C16:0-GlcCer) to 25-NBD-cholesterol despite the 
long reaction time (20 h). Almost the same results were 
observed in cell lysates incubated with natural GlcCer 
(C18:0-GlcCer or C24:1-GlcCer) as donor (data not shown). 
as glycose donors in the transglycosylation catalyzed by 
GBA or GBA2 (see supplementary Fig. 3). This was not 
observed. 
 We next studied whether natural GlcChol (100   M) can 
also act as donor in transglucosylation by incubating rGBA 
and lysates of cells overexpressing GBA2 or GBA3 in the 
presence of NBD-ceramide (40   M) as acceptor. Lysates 
of cells overexpressing GBA2 and rGBA showed formation 
of fl uorescent NBD-GlcCer ( Fig. 3C ). This was not ob-
served for lysates with overexpressed GBA3 ( Fig. 3C ). 
Transglucosylation by both GBA and GBA2 occurs as an 
 Fig. 3. In vitro transglucosylation of 25-NBD-GlcChol by GBA and GBA2. A: rGBA and lysates of cells with overexpression of GBA2, GBA3, 
and GCS were incubated for 0 and 1 h with 25-NBD-cholesterol in the presence of C18:1-GlcCer as donor, and in the absence or presence 
of the respective specifi c   -glucosidase inhibitors: CBE (GBA), AMP-DNM (GBA2), and anDIX (GBA3) ( 26 ). Formation of 25-NBD-
GlcChol was detected by HPTLC and fl uorescence scanning. B: rGBA (in absence or presence of CBE) and lysates of cells with overexpres-
sion of GBA2 (in presence of CBE and in absence or presence of AMP-DNM) were incubated for 0 and 1 h with cholesterol in the presence 
of C18:1-GlcCer as donor. Formation of GlcChol was detected by LC-MS. The percentage of inhibition of GlcChol formation by the respec-
tive inhibitors is shown. Data presented as mean ± SD. C: rGBA and lysates of cells with overexpression of GBA2 and GBA3 were incubated 
for 0 and 1 h with GlcChol in the presence of NBD-Cer. Formation of NBD-GlcCer was detected by HPTLC and fl uorescence scanning. D: 
  -Glucosidase activity in lysates of CHO-K1 cells overexpressing GBA3. The activity was measured in the absence or presence of the specifi c 
  -glucosidase inhibitors: 0.5 mM CBE and/or 0.3 mM NB-DGJ. CBE- and NB-DGJ-sensitive activities were defi ned as activities derived from 
GBA (black box) and GBA2 (gray box), respectively. CBE- and NB-DGJ-insensitive activity was defi ned as activity derived from GBA3 (dot-
ted box). Mock represents the cells transfected with empty vector. E: Transglucosylase activity in lysates of cells with overexpression of 
GBA3. Data (n = 3, mean ± SD) were analyzed using an unpaired  t -test. * P < 0.05 and ** P < 0.01. Black, gray, and dotted lines show the 
signifi cant difference of the activity derived from GBA, GBA2, and GBA3, respectively. 
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measured glucosylated sterol was examined by digestion 
with rGBA. While more than 90% of the GlcChol in the 
livers of WT mice was digested to cholesterol, in the case 
of material from NPC mice, this was only around 70% (not 
shown). Based on this fi nding, it seems likely that part of 
the elevated compound with  m/z 566.6 > 369.4 in NPC 
liver consists of cholesterol molecules modifi ed differently 
with sugar, indistinguishable from glucosyl-  -D-cholesterol 
with the LC-MS method. 
 To experimentally substantiate the observations made 
for GlcChol in the livers of NPC mice, we induced im-
paired cholesterol export from lysosomes in murine 
macrophage RAW264.7 cells by exposure to U18666A 
( 42 ). Following lysosomal cholesterol accumulation, cells 
showed elevated GlcChol. Concomitant inhibition of lyso-
somal GBA by CBE prevented the increase of GlcChol in 
U18666A-exposed cells ( Fig. 5C ). Formation of excessive 
GlcChol was also prevented by the presence of 1 mM 
  -methyl-cyclodextrin, an agent known to reduce intraly-
sosomal cholesterol in NPC cells ( 43 ). This indicates that 
during extreme intralysosomal accumulation of choles-
terol, GBA actively generates GlcChol. In normal lyso-
somes GBA most likely largely degrades the glucosylated 
sterol. 
 GlcChol in NPC and GD patients 
 Finally, we determined GlcChol levels in the plasma of 
untreated symptomatic type 1 GD patients, as well as in 
NPC patients, carriers, and healthy controls. As shown in 
 Fig. 6A , GlcChol tends to be increased in the plasma of 
symptomatic GD patients and less prominently in that of 
NPC patients. The abnormalities in GD patients are more 
pronounced when plasma GlcChol is related to choles-
terol ( Fig. 6B ). Investigation of plasma specimens of type 
1 GD patients treated with the GCS inhibitor, eliglustat 
( Fig. 6C ), showed a prominent reduction upon inhibition 
of GSL synthesis. Treatment of matched patients with the 
weaker GCS inhibitor, miglustat (Zavesca ® , Actelion) also 
led to a reduction of GlcChol, albeit more slowly ( Fig. 6C ). 
Of note, treatment of matched patients with rGBA Cer-
ezyme (ERT) did not reduce GlcChol to the same extent, 
 Molecular docking of GlcChol in the GBA crystal struc-
ture was performed (see supplementary Fig. 4). The li-
gand GlcChol was built and regularized with ligand and 
superimposed on the bicyclic nojirimycin analog ligand 
that was crystallized in complex with GBA (protein data 
bank code 2XWE) using the program, Coot (see supple-
mentary Methods ). GlcChol was found to be positioned 
such that the glucosidic bond is accessible to the catalytic 
residues Glu235 and Glu340. The cholesterol moiety con-
comitantly interacts with aromatic side chains. 
 Metabolism of GlcChol in cultured COS-7 cells 
 Next we studied factors infl uencing the formation of 
GlcChol content in cultured green monkey kidney COS-7 
cells. We fi rst studied the impact of overexpressed GBA2 
and GCS.  Figure 4 shows the effect on cellular GlcChol 
and GlcCer levels. Only overexpression of GCS led to 
increased levels of GlcCer ( Fig. 4A ). GlcChol was not 
changed by overexpression of GBA2, but overexpression 
of GCS caused a 12-fold increase in this lipid. Importantly, 
inhibition of GBA2 activity with low nanomolar AMP-DNM 
( 38 ) resulted in reduced cellular GlcChol. Even in cells 
with overexpressed GCS, the elevation in GlcChol was pre-
vented ( Fig. 4B ). In contrast, inhibition of GBA with CBE 
hardly diminished the increased GlcChol level in cells with 
overexpressed GCS. These fi ndings suggest that GCS does 
not generate GlcChol itself, but is required to generate 
suffi cient GlcCer to be used as donor in formation of 
GlcChol by transglucosylation. This transglucosylation in 
COS-7 cells is particularly mediated by GBA2, and not 
GBA. The latter notion is consistent with the fi nding that 
GBA2 defi ciency in mice, and not that of GBA, is accompa-
nied with reduced GlcChol levels of tissues. 
 GlcChol in NPC mice and U18666A-treated cells 
 In NPC disease, cholesterol accumulates prominently in 
lysosomes as the result of impaired export from the com-
partment due to defects in either  Npc1 or  Npc2 . In the liv-
ers of spontaneous  Npc1 nih/nih ( 29, 39, 40 ) and  Npc1 spm/spm 
mice ( 30, 41 ), we observed a remarkable 25-fold increase 
in GlcChol content ( Fig. 5A, B ). The identity of the 
 Fig. 4. GlcChol in COS-7 cells manipulated in GSL-metabolizing enzymes. A: GlcCer (nanomoles per mil-
ligram protein) in COS-7 cells without overexpression of enzymes (control), overexpressed GBA2, and GCS. 
Cells were incubated for 2 days with the indicated inhibitors of GBA2 (AMP-DNM) and GBA (CBE). B: 
GlcChol (picomoles per milligram protein) in same cells. Data (n = 4, mean ± SD) were analyzed using an 
unpaired  t -test. *** P < 0.001 Q22. 
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in vitro. Artifi cial   -glucosides, like 4MU-Glc, may act as 
donor in this reaction in vitro, as well as natural GlcCer . 
GlcChol is, on the other hand, also an excellent substrate 
for hydrolysis by GBA. Our fi ndings suggest that GBA nor-
mally lowers GlcChol levels. GBA-defi cient LIMP2 KO 
mice show modestly elevated GlcChol in several tissues 
and the same is observed in GBA null/fl ox mice with induced 
type 1 GD ( 32 ). Finally, plasma GlcChol is elevated in 
symptomatic type 1 GD patients. The actual role played by 
GBA in GlcChol metabolism, degradation versus synthesis, 
might be highly dependent on local concentrations of do-
nors (GlcCer and GlcChol) and acceptors (ceramide and 
cholesterol) in the transglucosylation equilibrium of the 
enzyme. The importance of this is suggested by some ob-
servations made in the course of our investigation. In the 
fi rst place, high intralysosomal cholesterol concentrations 
appear to favor formation of GlcChol by GBA. This is indi-
cated by the 25-fold elevated GlcChol in the liver of two 
different models of NPC disease in mice. In accordance 
with this, induction of lysosomal cholesterol accumulation 
with U18666A in cells causes a rapid increase in GlcChol, 
which was noted to be abolished by inactivation of GBA. 
Consequently, under normal conditions, GBA seems to 
promote GlcChol degradation, but under excess choles-
terol accumulation in lysosomal membrane, such as that 
found in NPC, the equilibrium of the metabolism is al-
tered to favor GlcChol formation by GBA. 
 We observed that the nonlysosomal   -glucosidase, GBA2, 
can also generate GlcChol through transglucosylation in 
vitro. Again, GlcCer was found to be an excellent donor 
for this reaction. GBA2 is equally able to degrade GlcChol. 
Our fi nding of reduced GlcChol levels in GBA2 KO mice 
suggests, but does not entirely prove, that GBA2 in vivo 
contributes to the presence of GlcChol. The enzyme GBA2 
is located differently in cells from lysosomal GBA, with its 
despite impressive clinical improvements in these patients 
( Fig. 6C ) (B. E. Smid et al., unpublished observations ). 
 DISCUSSION 
 Recently, Akiyama and colleagues ( 11 ) demonstrated that 
GBA, either pure recombinant protein or enzyme in fi bro-
blast lysates, can generate GlcChol by transglucosylation of 
cholesterol when provided with GlcCer as donor . The 
physiological signifi cance of glucosylation of cholesterol is 
hypothetically great because it renders a molecule far 
more water soluble. To establish the natural occurrence of 
GlcChol in mammals, we fi rst needed to develop a quanti-
tative and sensitive assay for quantifi cation of GlcChol in 
plasma, cells, and tissues. The method developed by us 
makes use of newly synthesized  13 C 6 -GlcChol as internal 
standard. Regarding extraction effi ciency, chromatographic 
behavior, and ionization characteristics, the natural and 
isotope-labeled compounds are identical, so no correction 
for the sample matrix (ion suppression or ion enhance-
ment) is required. 
 With sensitive quantifi cation of GlcChol in place, we 
next observed that almost all tissues of mice show GlcChol. 
The relative high amount of the glucosylated sterol in the 
thymus, several nanomoles per gram wet weight, is striking 
and deserves special attention in view of noted abnormali-
ties in NKT and B-cells in GBA-defi cient GD patients ( 44 ). 
It has been speculated by Mistry and colleagues that ele-
vated GlcCer or GlcSph, via binding to CD1, may cause 
this phenomenon ( 44 ). It will now be of interest to study 
whether GlcChol interacts with CD1 because abnormali-
ties in concentration of this lipid in GBA-defi cient GD pa-
tients are likely. 
 Indeed, we recapitulated the fi nding that GBA is able to 
form GlcChol by transglucosylation of cholesterol, at least 
 Fig. 5. GlcChol abnormalities in NPC. A: GlcChol (nanomoles per gram wet weight) in liver of BALB/c 
 Npc1 +/+ ,  Npc1 +/nih and  Npc1 nih/nih male mice at 80 days of age (n = 3, mean ± SD). B: GlcChol (nanomoles per 
gram wet weight) in liver of C57BLKS  Npc1 +/spm and  Npc1 spm/spm male mice at 80 days of age (n = 3–5, mean ± 
SD). C: GlcChol (picomoles per milligram protein) in RAW264.7 cells incubated with the indicated concen-
tration of U18666A for 1 day in the absence and presence of CBE-inhibiting GBA (n = 3, mean ± SD). D: 
GlcChol picomoles per milligram protein) in RAW264.7 cells incubated with 10   M U18666A for 8 h and in 
the subsequent absence or presence of 1 mM   -methyl-cyclodextrin (  -mCD) reducing intralysosomal cho-
lesterol for 18 h (n = 3, mean ± SD). Data were analyzed using an unpaired  t -test. ** P < 0.01, and *** P < 
0.001 . 
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 GlcChol is far more water soluble than cholesterol and, 
therefore, more suited for transport. The relatively low 
steady concentration of GlcChol does not exclude a vital 
role as intermediate in a transport pathway. Tentatively, 
water soluble GlcChol formed by transglucosylation at one 
cellular site would be transported and reconverted at the 
destination site back to more inert cholesterol. The combi-
nation of the two enzymes, GBA and GBA2, could provide 
such a mechanism without need for ATP. Of interest, in 
view of this speculation, is that LIMP2, the membrane pro-
tein interacting with GBA, has recently been shown to 
have a cholesterol binding site and potentially even a tun-
nel/channel function ( 45 ). 
 A fi nal consideration concerns the possible pathophysi-
ological consequences of disturbed GlcChol metabolism. 
It seems likely that in individuals with abnormal GlcCer 
metabolism, as for example GBA-defi cient GD patients, 
secondary abnormalities in GlcChol occur. Future re-
search will need to reveal whether such abnormalities in 
GlcChol or in other glucosylated metabolites contribute to 
particular symptoms associated with GD. In conclusion, 
GlcCer has earlier been identifi ed as an important struc-
tural membrane component and intermediate in GSL bio-
synthesis. In addition, it is known to act as an important 
sink for pro-apoptotic ceramide ( 46, 47 ). Our study suggests 
catalytic pocket exposed to the cytoplasmic leafl et of mem-
branes. It likely encounters different concentrations of 
GlcCer and cholesterol than GBA, given its location close 
to the cellular sites of de novo synthesis of these lipids. To 
maximally form GlcChol through transglucosylation, high 
concentrations of GlcCer as donor and high concentra-
tions of cholesterol as acceptor are optimal. Vice versa, low 
concentrations of GlcCer and cholesterol will reduce net 
GlcChol formation. This consideration holds equally for 
GBA2 and GBA. Fluctuations in sterols and sphingolipids 
conceivably occur in cells, for example, after uptake of 
cholesterol-rich lipoproteins or upon release of ceramide 
from sphingomyelin. The ability to maintain some equilib-
rium between (glucosylated) sphingolipids and sterols by 
transglucosylating   -glucosidases may have benefi cial buff-
ering effects for cells. Of interest in this respect is our fi nd-
ing that inhibition of GCS leads to reduction of GlcChol in 
cultured cells, plasma of mice, and plasma of GD patients. 
This strongly suggests that the availability of GlcCer is an 
important driver of formation of GlcChol through transglu-
cosylation. Because the   -glucosidases, GBA and GBA2, also 
hydrolyze GlcCer, and thus tend to lower its concentra-
tion, the exquisite balance of various GlcCer-metabolizing 
enzymes and local cholesterol concentrations will deter-
mine GlcChol formation in subcellular compartments. 
 Fig. 6. Plasma GlcChol in lysosomal storage disease patients and healthy individuals. A: Plasma GlcChol 
(nanomolar) in healthy individuals, type 1 GD patients, NPC carriers, and NPC patients. B: Ratio of GlcChol/
cholesterol (Chol) in plasma of healthy individuals, type 1 GD patients, NPC carriers, and NPC patients. C: 
Percentage reduction in plasma GlcChol of matched type 1 GD patients following eliglustat, miglustat, and 
ERT treatment compared with pretreatment values. Data were analyzed using the Mann-Whitney U test. 
** P < 0.01, and *** P < 0.001. 
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